Navigation Links
Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report
Date:1/6/2009

TUSTIN, Calif., Jan. 6 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with operations in China and the US, announced today industry analyst Lauren Rudd has issued a strong buy recommendation for AMDL in his year-end financial research report on the Company.

The report projects a 12-month target price of $5.00 for AMDL and highlights the Company's:

    -- Consistent, positive historical financial performance over the past
       four years
    -- Most recent operational changes and business updates, including an
       updated overview of AMDL's China-based subsidiary Jade Pharmaceuticals,
       Inc.
    -- FY2009 product pipeline
    -- FY2009 plans for the AMDL ELISA DR-70(R) (FDP) cancer monitoring test;
       best-selling Human Placenta Extract (HPE) anti-aging product line; and
       MYHPV Chip(R) diagnostic test kit which detects approximately 28
       different strains of the Human Papilloma Virus.

The research report also provides a thorough peer group comparison with valuation analyses, views and opinions on AMDL's projected financial performance for the 2009 fiscal year, and historical financials.

According to Mr. Rudd, "AMDL has taken major initiatives to build its strengths while reorganizing top management and still producing respectable financials which has resulted in AMDL being one of the most under priced stocks we have seen in a long time."

A full copy of the report is available for downloading online at http://www.ruddreport.com or by contacting Ms. Kristine Szarkowitz, AMDL's Director Investor Relations, at kszarkowitz@amdl.com.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

     AMDL Contact:
     Kristine Szarkowitz
     Director-Investor Relations
     kszarkowitz@amdl.com
     (Tel :) 206.310.5323

'/>"/>
SOURCE AMDL, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Consumer Reports: Big Promises of Some Infomercial Exercise Machines Fall Flat; Plus, Set Up a Home Gym for Under $100
2. Cardium Reports on Exchange Listing With NYSE Alternext US
3. CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes
4. Joint Commission Reports Positive Survey Results for CHA
5. Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability
6. Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability
7. Risks and Benefits of Egg Donation Reported
8. LegalView Updates its Baxter Heparin Information Portal with Conflicting News Reports on the Possible Dangers
9. Despite Sagging Economy, Viamedic Reports Solid Online Sales for Erectile Dysfunction Drugs
10. 5,000 Medical Leaders Report Latest Advancements in Biomedical Technologies; Breakthroughs by 2015 Predicted for Alzheimer's, Heart Disease, Cancer, and Diabetes
11. Published reports inaccurate concerning alcohol consumption during pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... , ... August 17, 2017 , ... When Amy ... stretcher side nurse, she took with her a dream to make nursing education more ... Specifically, ensuring communication skills were integrated into healthcare provider education. , ...
(Date:8/17/2017)... ... August 17, 2017 , ... Brookfield, ... for healthcare, hospitality and education, is celebrating its 30th year in business this ... begun at manufacturing companies Square D, Allis Chalmers and Johnson Controls. Following his ...
(Date:8/17/2017)... ... 2017 , ... Aeroflow Healthcare today announced its placement on ... private companies. Inc. magazine ranked Aeroflow Healthcare #2450 on its annual list, showcasing ... Inc. 5000 represents the most comprehensive study of American entrepreneurial enterprises based on ...
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article on ... plastic surgery, largely influenced by the growing popularity of “pretty boys” in both K-Pop ... that standards of male appearance are changing not only in the Asian nation, where ...
(Date:8/17/2017)... ... August 17, 2017 , ... Pot Valet is a leading provider of premium ... in the state, and soon, every state in the country, the company offers patients ... cannabis dispensary altogether. , According to Pot Valet, all California patients have ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
(Date:7/28/2017)... --EnvoyHealth, a Diplomat company, has partnered with Compliance Meds ... a technology designed to improve patient medication adherence. ... solutions and services that help track and improve patients, ... LITE offers medication monitoring and control for patients and ... Records date and time of bottle ...
Breaking Medicine Technology: